Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Post Covid Potential of 5-15 billion annual Revenue

<< Previous

Bullboard Posts

Next >>

Post by Riverfolkon Feb 14, 2021 2:17pm

168 Views

Post# 32565161

Post Covid Potential of 5-15 billion annual Revenue

“But if (Metablok) is found to be useful in a situation like COVID, it could be useful in many other situations that will continue to occur even when the pandemic is over. So it’s got potential well beyond COVID, which is another great reason we were interested in helping out with the trial.”

Kidney - 5 billion
lung - 8-10 billion
liver - TBD

<< Previous

Bullboard Posts

Next >>

Infield Minerals to acquire Kings Canyon Gold Property